» Articles » PMID: 30059958

PTPN11 Gain-of-Function Mutations Affect the Developing Human Brain, Memory, and Attention

Overview
Journal Cereb Cortex
Specialty Neurology
Date 2018 Jul 31
PMID 30059958
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The Ras-MAPK pathway has an established role in neural development and synaptic signaling. Mutations in this pathway are associated with a collection of neurodevelopmental syndromes, Rasopathies; among these, Noonan syndrome (NS) is the most common (1:2000). Prior research has focused on identifying genetic mutations and cellular mechanisms of the disorder, however, effects of NS on the human brain remain unknown. Here, imaging and cognitive data were collected from 12 children with PTPN11-related NS, ages 4.0-11.0 years (8.98 ± 2.33) and 12 age- and sex-matched typically developing controls (8.79 ± 2.17). We observe reduced gray matter volume in bilateral corpus striatum (Cohen's d = -1.0:-1.3), reduced surface area in temporal regions (d = -1.8:-2.2), increased cortical thickness in frontal regions (d = 1.2-1.3), and reduced cortical thickness in limbic regions (d = -1.6), including limbic structures integral to the circuitry of the hippocampus. Further, we find high levels of inattention, hyperactivity, and memory deficits in children with NS. Taken together, these results identify effects of NS on specific brain regions associated with ADHD and learning in children. While our research lays the groundwork for elucidating the neural and behavioral mechanisms of NS, it also adds an essential tier to understanding the Ras-MAPK pathway's role in human brain development.

Citing Articles

Brain volumes in genetic syndromes associated with mTOR dysregulation: a systematic review and meta-analysis.

Payne J, Haebich K, Mitchell R, Bozaoglu K, Giliberto E, Lockhart P Mol Psychiatry. 2024; .

PMID: 39633008 DOI: 10.1038/s41380-024-02863-4.


Social Communication in Ras Pathway Disorders: A Comprehensive Review From Genetics to Behavior in Neurofibromatosis Type 1 and Noonan Syndrome.

Siqueiros-Sanchez M, Serur Y, McGhee C, Smith T, Green T Biol Psychiatry. 2024; 97(5):461-498.

PMID: 39366539 PMC: 11805629. DOI: 10.1016/j.biopsych.2024.09.019.


Paternally Inherited Noonan Syndrome Caused by a Variant May Exhibit Mild Symptoms: A Case Report and Literature Review.

Han J, Park J Genes (Basel). 2024; 15(4).

PMID: 38674380 PMC: 11050143. DOI: 10.3390/genes15040445.


Influences of RASopathies on Neuroanatomical Variation in Children.

McGhee C, Honari H, Siqueiros-Sanchez M, Serur Y, van Staalduinen E, Stevenson D Biol Psychiatry Cogn Neurosci Neuroimaging. 2024; 9(9):858-870.

PMID: 38621478 PMC: 11381177. DOI: 10.1016/j.bpsc.2024.04.003.


Molecular basis underlying changes of brain entropy and functional connectivity in major depressive disorders after electroconvulsive therapy.

Yu X, Chen K, Ma Y, Bai T, Zhu S, Cai D CNS Neurosci Ther. 2024; 30(3):e14690.

PMID: 38529527 PMC: 10964037. DOI: 10.1111/cns.14690.


References
1.
Feng G . Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res. 1999; 253(1):47-54. DOI: 10.1006/excr.1999.4668. View

2.
Schmitt J, Eliez S, Bellugi U, Reiss A . Analysis of cerebral shape in Williams syndrome. Arch Neurol. 2001; 58(2):283-7. DOI: 10.1001/archneur.58.2.283. View

3.
Tonks N, Neel B . Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol. 2001; 13(2):182-95. DOI: 10.1016/s0955-0674(00)00196-4. View

4.
Tartaglia M, Mehler E, Goldberg R, Zampino G, Brunner H, Kremer H . Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29(4):465-8. DOI: 10.1038/ng772. View

5.
Neel B, Gu H, Pao L . The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003; 28(6):284-93. DOI: 10.1016/S0968-0004(03)00091-4. View